AB-103
| Clinical data | |
|---|---|
| Other names | AB103 |
| Routes of administration | Topical[1] |
| Drug class | Minoxidil sulfotransferase stimulant |
AB-103 is a minoxidil sulfotransferase stimulant which is under development for the treatment of alopecia (hair loss) as an adjunct to the hair loss drug minoxidil.[1] It is used topically.[1] The drug works by stimulating the enzyme SULT1A1 in hair follicles which converts minoxidil into its active form minoxidil sulfate and which has been found to predict minoxidil's clinical effectiveness.[1][2][3][4] It was originated by Applied Biology and is under development by Safety Shot.[1] As of February 2024, AB-103 is in phase 3 clinical trials for treatment of alopecia.[1] It has been in this stage of development since at least April 2019, but there have been no more recent updates on its development since then.[1] The chemical structure of AB-103 does not yet appear to have been disclosed.[1]
See also
[edit]References
[edit]- 1 2 3 4 5 6 7 8 "AB 103". AdisInsight. 27 February 2024. Retrieved 23 October 2025.
- ↑ Goren A, Naccarato T (September 2018). "Minoxidil in the treatment of androgenetic alopecia". Dermatologic Therapy. 31 (5) e12686. doi:10.1111/dth.12686. PMID 30155952.
- ↑ Roberts J, Desai N, McCoy J, Goren A (2014). "Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia". Dermatologic Therapy. 27 (4): 252–254. doi:10.1111/dth.12130. PMID 24773771.
- ↑ Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, et al. (2015). "Clinical utility and validity of minoxidil response testing in androgenetic alopecia". Dermatologic Therapy. 28 (1): 13–16. doi:10.1111/dth.12164. PMID 25112173.
 | This dermatologic drug article is a stub. You can help Wikipedia by adding missing information. |